Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1993 Oct;70(4):382–385. doi: 10.1136/hrt.70.4.382

Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterisation in infants and children.

W Zenz 1, W Muntean 1, A Beitzke 1, G Zobel 1, M Riccabona 1, A Gamillscheg 1
PMCID: PMC1025337  PMID: 8217450

Abstract

OBJECTIVE--To determine the efficacy of fibrinolytic therapy with tissue plasminogen activator (alteplase) in infants and children with arterial thrombosis after cardiac catheterisation. DESIGN--Use of alteplase (Actilyse) in a protocol with prospective data collection. Alteplase was administered to infants and children with arterial thrombosis after cardiac catheterisation. A dose of 0.5 mg/kg/h was given continuously via a peripheral vein for the first hour followed by 0.25 mg/kg/h till clot lysis occurred or treatment had to be stopped because of bleeding complications. SETTING--University hospital, intensive care unit. PATIENTS--17 consecutive infants and children with femoral artery thrombosis after cardiac catheterisation between 1 April 1988 and 31 October 1991. MAIN OUTCOME MEASURE--Reopening of the vessel. RESULTS--Complete clot lysis was achieved in 16 of 17 patients within 4-11 hours after the start of treatment. In one patient only partial lysis occurred. After complete lysis rethrombosis developed in one patient 15 hours after the end of treatment. Bleeding complications were seen in nine patients. These were restricted to the arterial puncture site, except for one who showed mild epistaxis. Three patients had to be treated with packed erythrocytes. CONCLUSIONS--Alteplase was an effective treatment of arterial thrombosis after cardiac catheterisation in infants and children. Further studies are needed to determine whether lower doses will reduce the frequently observed bleeding complications.

Full text

PDF
382

Images in this article

383Image
on p.383
383Image
on p.383

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson B. J., Keeley S. R., Johnson N. D. Caval thrombolysis in neonates using low doses of recombinant human tissue-type plasminogen activator. Anaesth Intensive Care. 1991 Feb;19(1):22–27. doi: 10.1177/0310057X9101900104. [DOI] [PubMed] [Google Scholar]
  2. Beitzke A., Mache C. J., Stein J. I., Suppan C. Komplikationen bei zwei Serien von je 1000 Herzkatheteruntersuchungen im Kindesalter. Wien Klin Wochenschr. 1991;103(3):75–81. [PubMed] [Google Scholar]
  3. Bounameaux H., Banga J. D., Bluhmki E., Coccheri S., Fiessinger J. N., Haarmann W., Lockner D., Mahler F., Ninet J., Schneider P. A. Double-blind, randomized comparison of systemic continuous infusion of 0.25 versus 0.50 mg/kg/24 h of alteplase over 3 to 7 days for treatment of deep venous thrombosis in heparinized patients: results of the European Thrombolysis with rt-PA in Venous Thrombosis (ETTT) trial. Thromb Haemost. 1992 Mar 2;67(3):306–309. [PubMed] [Google Scholar]
  4. Brus F., Witsenburg M., Hofhuis W. J., Hazelzet J. A., Hess J. Streptokinase treatment for femoral artery thrombosis after arterial cardiac catheterisation in infants and children. Br Heart J. 1990 May;63(5):291–294. doi: 10.1136/hrt.63.5.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Burrows P. E., Benson L. N., Williams W. G., Trusler G. A., Coles J., Smallhorn J. F., Freedom R. M. Iliofemoral arterial complications of balloon angioplasty for systemic obstructions in infants and children. Circulation. 1990 Nov;82(5):1697–1704. doi: 10.1161/01.cir.82.5.1697. [DOI] [PubMed] [Google Scholar]
  6. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost. 1980 Jun 18;43(2):77–89. [PubMed] [Google Scholar]
  7. Collen D., Stump D. C., Gold H. K. Thrombolytic therapy. Annu Rev Med. 1988;39:405–423. doi: 10.1146/annurev.me.39.020188.002201. [DOI] [PubMed] [Google Scholar]
  8. Doyle E., Britto J., Freeman J., Munro F., Morton N. S. Thrombolysis with low dose tissue plasminogen activator. Arch Dis Child. 1992 Dec;67(12):1483–1484. doi: 10.1136/adc.67.12.1483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Flanigan D. P., Keifer T. J., Schuler J. J., Ryan T. J., Castronuovo J. J. Experience with latrogenic pediatric vascular injuries. Incidence, etiology, management, and results. Ann Surg. 1983 Oct;198(4):430–442. doi: 10.1097/00000658-198310000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Freed M. D., Keane J. F., Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children. Circulation. 1974 Sep;50(3):565–569. doi: 10.1161/01.cir.50.3.565. [DOI] [PubMed] [Google Scholar]
  11. Girod D. A., Hurwitz R. A., Caldwell R. L. Heparinization for prevention of thrombosis following pediatric percutaneous arterial catheterization. Pediatr Cardiol. 1982;3(2):175–180. doi: 10.1007/BF02312966. [DOI] [PubMed] [Google Scholar]
  12. Hsia J., Hamilton W. P., Kleiman N., Roberts R., Chaitman B. R., Ross A. M. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med. 1990 Nov 22;323(21):1433–1437. doi: 10.1056/NEJM199011223232101. [DOI] [PubMed] [Google Scholar]
  13. Hurwitz R. A., Franken E. A., Jr, Girod D. A., Smith J. A., Smith W. L. Angiographic determination of arterial patency after percutaneous catheterization in infants and small children. Circulation. 1977 Jul;56(1):102–105. doi: 10.1161/01.cir.56.1.102. [DOI] [PubMed] [Google Scholar]
  14. Ino T., Benson L. N., Freedom R. M., Barker G. A., Aipursky A., Rowe R. D. Thrombolytic therapy for femoral artery thrombosis after pediatric cardiac catheterization. Am Heart J. 1988 Mar;115(3):633–639. doi: 10.1016/0002-8703(88)90815-0. [DOI] [PubMed] [Google Scholar]
  15. Kennedy L. A., Drummond W. H., Knight M. E., Millsaps M. M., Williams J. L. Successful treatment of neonatal aortic thrombosis with tissue plasminogen activator. J Pediatr. 1990 May;116(5):798–801. doi: 10.1016/s0022-3476(05)82675-7. [DOI] [PubMed] [Google Scholar]
  16. Leblanc J., Wood A. E., O'Shea M. A., Williams W. G., Trusler G. A., Rowe R. D. Peripheral arterial trauma in children. A fifteen year review. J Cardiovasc Surg (Torino) 1985 Jul-Aug;26(4):325–331. [PubMed] [Google Scholar]
  17. Levin E. G. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci U S A. 1983 Nov;80(22):6804–6808. doi: 10.1073/pnas.80.22.6804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Levy M., Benson L. N., Burrows P. E., Bentur Y., Strong D. K., Smith J., Johnson D., Jacobson S., Koren G. Tissue plasminogen activator for the treatment of thromboembolism in infants and children. J Pediatr. 1991 Mar;118(3):467–472. doi: 10.1016/s0022-3476(05)82170-5. [DOI] [PubMed] [Google Scholar]
  19. Mansfield P. B., Gazzaniga A. B., Litwin S. B. Management of arterial injuries related to cardiac catheterization in children and young adults. Circulation. 1970 Sep;42(3):501–507. doi: 10.1161/01.cir.42.3.501. [DOI] [PubMed] [Google Scholar]
  20. Marder V. J., Sherry S. Thrombolytic therapy: current status (1). N Engl J Med. 1988 Jun 9;318(23):1512–1520. doi: 10.1056/NEJM198806093182306. [DOI] [PubMed] [Google Scholar]
  21. Marder V. J., Sherry S. Thrombolytic therapy: current status (2). N Engl J Med. 1988 Jun 16;318(24):1585–1595. doi: 10.1056/NEJM198806163182406. [DOI] [PubMed] [Google Scholar]
  22. Pyles L. A., Pierpont M. E., Steiner M. E., Hesslein P. S., Smith C. M., 2nd Fibrinolysis by tissue plasminogen activator in a child with pulmonary embolism. J Pediatr. 1990 May;116(5):801–804. doi: 10.1016/s0022-3476(05)82676-9. [DOI] [PubMed] [Google Scholar]
  23. Stanger P., Heymann M. A., Tarnoff H., Hoffman J. I., Rudolph A. M. Complications of cardiac catheterization of neonates, infants, and children. A three-year study. Circulation. 1974 Sep;50(3):595–608. doi: 10.1161/01.cir.50.3.595. [DOI] [PubMed] [Google Scholar]
  24. Strife J. L., Ball W. S., Jr, Towbin R., Keller M. S., Dillon T. Arterial occlusions in neonates: use of fibrinolytic therapy. Radiology. 1988 Feb;166(2):395–400. doi: 10.1148/radiology.166.2.3336714. [DOI] [PubMed] [Google Scholar]
  25. Wessel D. L., Keane J. F., Fellows K. E., Robichaud H., Lock J. E. Fibrinolytic therapy for femoral arterial thrombosis after cardiac catheterization in infants and children. Am J Cardiol. 1986 Aug 1;58(3):347–351. doi: 10.1016/0002-9149(86)90075-5. [DOI] [PubMed] [Google Scholar]
  26. White J. J., Talbert J. L., Haller J. A., Jr Peripheral artial injuries in infants and children. Ann Surg. 1968 May;167(5):757–766. doi: 10.1097/00000658-196805000-00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. de Bono D. P., Simoons M. L., Tijssen J., Arnold A. E., Betriu A., Burgersdijk C., López Bescos L., Mueller E., Pfisterer M., Van de Werf F. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J. 1992 Feb;67(2):122–128. doi: 10.1136/hrt.67.2.122. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES